Join Actinium Pharmaceuticals for a virtual investor event featuring key opinion leader (KOL) Ehab Atallah, MD (Medical College of Wisconsin), who will join company management to discuss Actimab-A targeted radiotherapy for the treatment of acute myeloid leukemia (AML).

Actinium’s management will also provide a company update to highlight recent developments related to Actinium’s revitalized clinical programs and outline 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors, and cell and gene therapy conditioning including:

• Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes (MDS) across multiple treatment settings
• Actimab-A as a pan solid tumor therapy in combination with PD-1 inhibitors including KEYTRUDA and OPDIVO by depleting myeloid derived suppressor cells (MDSCs)
• Iomab-ACT as a universal targeted conditioning agent to increase patients access to cell & gene therapies and improve patient outcomes

Actimab-A has a mutation agnostic mechanism via the radioisotope payload Actinium-225 and backbone therapy potential in highly radiosensitive, mutation rich AML and myeloid malignancies with recent expansion into solid tumors in combination with PD-1 checkpoint inhibitors. Dr. Atallah and Management will discuss the planned pivotal Phase 2/3 trial for Actimab-A + CLAG-M and the recently initiated frontline AML triplet combination trial under an NCI CRADA with Venetoclax and ASTX-727, a novel hypomethylating agent developed by Taiho Oncology, an Otsuka Holdings company. In addition, Iomab-ACT is intended to be a universal next generation targeted conditioning solution for cellular therapies like CAR-T and gene therapies. The event will review Iomab-ACT’s commercial CAR-T trial and sickle cell disease trial. Clinical proof-of-concept data from these trials and from the newly initiated Actimab-A combinations with blockbuster PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO in solid tumor indications are expected in the second half of 2025.

A live question and answer session will follow the formal presentations.